Denise Mann is a freelance health writer based in New York. She specializes in medicine and healthcare, exploring topics such as dermatology, wellness programs, and the beauty industry, with a focus on aging and longevity. Denise's work has been featured in numerous outlets, including HealthDay News, Reader's Digest, and BuzzFeed News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Denise Mann's coverage predominantly focuses on healthcare, pharmaceuticals, and scientific topics related to dermatology and skin conditions. The majority of her articles cite data or are based on press releases. She appears to be interested in reporting on the latest medical research, FDA approvals, and developments within the field of skincare.
When reaching out to Denise Mann with pitches or expert commentary, consider offering access to new research findings, exclusive insights into clinical trials for dermatological treatments or FDA approval processes. Providing access to experts who can offer unique perspectives on emerging trends in dermatology and skin care could also be well received by Denise.
Given that there is no specified geographic focus for Denise Mann's work, she may cover global developments within dermatology and skin care fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Denise Mann
Living Well with Eczema, a free education program designed to help people move beyond just coping with eczema and toward living well with it, will take place in three cities in coming months. New York, NY August 1, 2026 Columbus, OH August 22, 2026 St. Louis, MO September 26, 2026 Living Well is for anyone who is: […]
By: Denise Mann
Tralokinumab’s (Adbry, Adtralza, LEO PHARMA) pharmacokinetic profile was consistent with what has previously been observed and generally well tolerated for up to 172 weeks of treatment, with no new safety signals in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2 TRAPEDS-1 trial. TRAPEDS-1 was a […]
By: Denise Mann
The first patient was successfully in Lynk Pharmaceuticals’ Phase 2 clinical trial evaluating LNK01004 ointment for the treatment of vitiligo. The Phase 2 study is a randomized, double-blind, vehicle-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of topically administered LNK01004 ointment in adult patients with vitiligo. LNK01004 ointment is a soft pan-Janus […]
Radiotherapy may eliminate cancer cells and reprogram the surrounding tumor microenvironment within cutaneous T-cell lymphoma (CTCL) tumors, according to a study in the Journal of the American Academy of Dermatology. “Our findings show that radiation does much more than kill lymphoma cells; it fundamentally reshapes the immune ecosystem surrounding the tumor,” says Co-senior Author Alan Zhou, MD, ‘21 […]
By: Denise Mann
Led by the International League of Dermatological Societies (ILDS) and the International Society of Dermatology (ISD), World Skin Health Day took place on July 8, 2026. This year’s theme—”Better Knowledge. Better Skin Health”—was reflected in each of the 15 projects funded by the ILDS and ISD, including “A is for Assurance: Building Skin Confidence in […]
By: Denise Mann
By Nikkia Zarabian, BS, and Mina Farah, BA Acne can carry significant psychosocial consequences for any patient, but these burdens may be amplified among sexual and gender minority (SGM) individuals, who already experience disproportionately high rates of mental health challenges, healthcare discrimination, and barriers to care, said Angelo Landriscina, MD, FAAD, a Board-certified Dermatologist at […]
Ampyrone, a nonsteroidal anti inflammatory (NSAID)-related compound, appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators. The discovery could lead to the development of an ampyrone-derived treatment for hypopigmentation disorders. The study, published in JCI Insight, was led by Jonathan […]
By: Denise Mann
L’Oréal Paris is launching Revitalift Melasyl Dark Spot Creamy-Serum to correct dark spots, improve skin tone, and smooth wrinkles. This marks the first time that L’Oréal Paris is integrating Melasyl into the Revitalift franchise. The formula is powered by Vitamin Cg and niacinamide. In a consumer test, 97% of women agreed their skin tone appeared more […]
By: Denise Mann
Neutrogena is rolling out Break the Rules, a new campaign designed to help consumers embrace science-backed solutions. “Patients now come in with routines built from social media — and often, half of it isn’t right for their skin. My advice: look for the science behind a product, not just the virality,” says Joshua Zeichner, MD, […]
By: Denise Mann
Zasocitinib (TAK-279, Takeda), a next-generation oral tyrosine kinase 2 (TYK2) inhibitor, showed consistent, high rates of skin clearance across the body, including hard-to-treat and high impact sites in adults with moderate-to-severe plaque psoriasis (PsO), according totwo pivotal Phase 3 studies presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York, NY. […]
